Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

Evan J. Lipson

doi:10.4161/onci.23660

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

Evan J. Lipson

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.

Original language	English (US)
Article number	e23660
Journal	OncoImmunology
Volume	2
Issue number	4
DOIs	https://doi.org/10.4161/onci.23660
State	Published - Apr 2013

Keywords

Anti-PD1
Cancer immunotherapy
Immune checkpoint blockade
Nivolumab
Re-induction

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.23660

Fingerprint Dive into the research topics of 'Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies'. Together they form a unique fingerprint.

Cite this

@article{b7458058f7df494ebc7e7b2e2ae3ddf3,

title = "Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies",

abstract = "The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.",

keywords = "Anti-PD1, Cancer immunotherapy, Immune checkpoint blockade, Nivolumab, Re-induction",

author = "Lipson, {Evan J.}",

year = "2013",

month = apr,

doi = "10.4161/onci.23660",

language = "English (US)",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

TY - JOUR

T1 - Re-orienting the immune system

T2 - Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

AU - Lipson, Evan J.

PY - 2013/4

Y1 - 2013/4

N2 - The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.

AB - The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.

KW - Anti-PD1

KW - Cancer immunotherapy

KW - Immune checkpoint blockade

KW - Nivolumab

KW - Re-induction

UR - http://www.scopus.com/inward/record.url?scp=84886943622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886943622&partnerID=8YFLogxK

U2 - 10.4161/onci.23660

DO - 10.4161/onci.23660

M3 - Article

C2 - 23734321

AN - SCOPUS:84886943622

VL - 2

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 4

M1 - e23660

ER -

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this